![]() ![]() Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, et al.Different doses of fingolimod in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. Wu X, Xue T, Wang Z, Chen Z, Zhang X, Zhang W, et al.Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis-a Portuguese cohort. Ramos-Lopes J, Batista S, Barradas P, Campelo I, Correia I, Nunes C, et al.Effectiveness of alternative dose fingolimod for multiple sclerosis. Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von GG, Chahin S, et al.Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MAL, et al.Drug holiday therapy of fingolimod in Japanese relapsing-remitting multiple sclerosis. Ohtani R, Masahiro M, Akiyuki U, Tomohiko U, Hiroki M, Satoshi K.A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al.Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al.Sphingosine-1-Phosphate: Its pharmacological regulation and the treatment of multiple sclerosis: A review article. ![]()
0 Comments
Leave a Reply. |